Kim Gemzoe
Overview
Explore the profile of Kim Gemzoe including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
59
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Petri M, Landy H, Clowse M, Gemzoe K, Khamashta M, Kurtinecz M, et al.
Ann Rheum Dis
. 2022 Oct;
82(2):217-225.
PMID: 36198440
Objective: Describe available data on birth defects and pregnancy loss in women with systemic lupus erythematosus (SLE) exposed to belimumab. Methods: Data collected from belimumab clinical trials, the Belimumab Pregnancy...
2.
Juliao P, Wurst K, Pimenta J, Gemzoe K, Landy H, Moody M, et al.
Birth Defects Res
. 2022 Sep;
115(2):188-204.
PMID: 36177676
Background: Belimumab is approved for active, autoantibody-positive systemic lupus erythematosus (SLE) and lupus nephritis, but limited data exist regarding its use in pregnancy. The Belimumab Pregnancy Registry (BPR, GSK Study...
3.
Pimenta J, Painter J, Gemzoe K, Levy R, Powell M, Meizlik P, et al.
JMIR Form Res
. 2022 May;
6(5):e30573.
PMID: 35612888
Background: Enrollment in pregnancy registries is challenging despite substantial awareness-raising activities, generally resulting in low recruitment owing to limited safety data. Understanding patient and physician awareness of and attitudes toward...
4.
Gemzoe K, Crawford R, Caress A, McCorkindale S, Conroy R, Collier S, et al.
Trials
. 2020 Sep;
21(1):798.
PMID: 32943093
Background: Randomized controlled trials (RCTs) conducted in the routine care setting provide the opportunity to better understand the effectiveness of new medicines but can present recruitment difficulties. An improved understanding...
5.
Harrison T, Canonica G, Chupp G, Lee J, Schleich F, Welte T, et al.
Eur Respir J
. 2020 Aug;
56(4).
PMID: 32817259
Introduction: Efficacy of mepolizumab, an anti-interleukin-5 monoclonal antibody, was demonstrated in randomised controlled trials; data on its real-world impact in routine clinical practice are starting to emerge. We assessed the...